AJAntti Jekunen

Antti Jekunen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antti Jekunen has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical factors associated with outcomes among patients receiving second-line therapy for advanced NSCLC

    by Vasileios Karagiannis, Levi Byskata, Nelli-Sofia Nåhls, Eero Sihvo, Antti Jekunen, Mikael Johansson, Heidi Andersén

  • Open Access

    Effect of Lung Cancer Screening, Smoking Cessation, and Cessation Smartphone App to Health-Related Quality of Life Among Heavy Smokers: Randomized Controlled Trial

    by Antti Kurtti, Sanna Iivanainen, Riitta Kaarteenaho, Heidi Andersen, Antti Jekunen, Tuula Vasankari, Jussi Koivunen

    Background: Lung cancer screening with low-dose computed tomography (LDCT) among heavy smokers can decrease lung cancer mortality. Smoking cessation intervention is recommended within the screening program; however, the methods for smoking cessation in the LDCT screening context are not well established. We have previously shown that a novel smartphone app can increase the chance for smoking cessation along with lung cancer screening. The effects of lung cancer screening, smoking cessation, and the use of smartphone apps on health-related quality of life (HRQoL) are widely unknown. Objective: This study aims to investigate the effect of lung cancer screening, smoking cessation, and the use of smoking cessation app on HRQoL, an exploratory end point of the low-dose computed tomography screening for lung cancer combined to different smoking cessation methods in Finland (LDCT-SC-FI) study. Methods: This study was conducted as a part of the LDCT-SC-FI (NCT05630950), which was a randomized controlled trial investigating different smoking cessation methods in participants undergoing lung cancer screening with LDCT. The main inclusion criteria included an age of 50‐74 years, a marked smoking history (smoked ≥15 cigarettes per day for ≥25 years or smoked ≥10 cigarettes per day for ≥30 years), an active smoking status, and access to a smartphone. The recruitment was carried out by newspaper and internet advertisements and informing relevant health care units at hospital districts. The study participants (n=200), all at Oulu University Hospital, were randomized in 1:1 fashion to a yearly LDCT with standard smoking cessation (written material) or a stand-alone smartphone app–based cessation. HRQoL, an exploratory study end point, was assessed at baseline and at 1 year with Quality of Life Questionnaire Core 30 (QLQ-C30) and EQ-5D. Results: In total, 199 and 186 individuals had both questionnaires completed at baseline and at 1 year, respectively. We did not detect a change in HRQoL between the time points using QLQ-C30 global health status score or EQ-5D index score. Smoking cessation at 1-year time did not affect QLQ-C30 global health status or EQ-5D. We observed improved quality of life scores by EQ-5D at 1 year (control: mean 0.720, SD 0.197 vs app: mean 0.799, SD 0.197; improved in 17/93, 18% of controls vs 29/93, 31% in app arm), while there was no difference in means at baseline. Smartphone app arm reported reduced pain (EQ-5D effect size [ES] 0.049, 95% CI 0.006‐0.12; P =.01; adjusted ES 0.026; P =.007; QLQ-C30 ES 0.076, 95% CI 0.02‐0.16; P <.001; adjusted ES 0.05; P =.02) and increased mobility (EQ-5D ES 0.031, 95% CI 0.01‐0.09; P =.02; adjusted ES 0.037; P =.008) at 1 year. The number of completed questionnaires in the app was associated with improved HRQoL by EQ-5D (ES 0.073, 95% CI 0.00‐0.180; P =.04; adjusted ES 0.071; P =.04). Conclusions: This is the first study to test a smoking cessation smartphone app in the context of lung cancer screening. The use of the developed app correlated with improved HRQoL, mainly by decreased pain and fatigue. To conclude, the studied app provides a feasible and effective cessation intervention that is readily implementable in population-based lung cancer screening programs, with enhanced health benefits beyond smoking cessation.

  • Open Access

    Comparative study of lung cancer care and survival outcomes across the Nordic countries

    by Ghida Khalife, Juho Waris, Uffe Bødtger, Johan Isaksson, Kirill Neumann, Hrönn Harðardóttir, Heidi Andersén, Antti Jekunen, Maria Lovén, Tuula Vasankari, et al.

    Background: Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. Despite societal, economic and genetic similarities, 5-year age-standardized relative survival rate is lower in Finland compared to the other Nordic countries. Previous studies have identified discrepancies in LC guidelines, but research on actual care practices remains limited. We aim to address this knowledge gap by conducting a comprehensive examination of the current care practices for LC patients in the Nordic countries. Methods: We employed a non-interventional, prospective study design. We conducted an expert workshop involving LC specialists from Finland to formulate relevant questions for a structured survey. This survey was distributed to healthcare professionals (HCPs) across Nordic hospitals and primary care units. The survey results were then analyzed, and a follow-up Nordic LC expert workshop was held to identify the most relevant factors potentially influencing LC survival outcomes. Results: Four key differences in care practices between Finland and other Nordic countries were identified: (1) resources available in primary care units, (2) waiting times in primary care, (3) availability of novel treatments and (4) tracking of LC survival and mortality outcomes by the hospital. Finland has the lowest access to computed tomography (CT) from primary care, longest waiting times in primary care, and lacks a national outcome tracking system. Some medical doctors in Finland and Iceland highlighted observed limitations in specific cases involving access to neoadjuvant immunotherapy and chemotherapy. Interpretation: Several factors unrelated to specialized LC care are likely contributing to poorer 5-year survival rates for LC in Finland. These findings may be applicable to other healthcare systems as well.


  • Open Access

    A systematic review and meta-analysis of lung cancer risk prediction models

    by Ghida Khalife, Matilda Nilsson, Lotta Peltola, Juho Waris, Antti Jekunen, Riikka-Leena Leskelä, Heidi Andersén, Mikko Nuutinen, Eija Heikkilä, Susanna Nurmi-Rantala, et al.

    Background: Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide. Early detection through targeted screening significantly improves patient outcomes. However, identifying high-risk individuals remains a critical challenge. Purpose: This systematic review evaluates externally validated LC risk prediction models to assess their performance and potential applicability in screening strategies. Methods: Of the 11,805 initial studies, 66 met inclusion criteria and 38 published mainly between 2020 and 2024 were included in the final analysis. Model methodologies, validation approaches, and performance metrics were extracted and compared. Results: The review identified 18 models utilising conventional machine learning, six employing neural networks, and 14 comparing different predictive frameworks. The Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCOm2012) demonstrated superior sensitivity across diverse populations, while newer models, such as Optimized Early Warning model for Lung cancer risk (OWL) and CanPredict, showed promising results. However, differences in population demographics and healthcare systems may limit the generalisability of these models. Interpretation: While LC risk prediction models have advanced, their applicability to specific healthcare systems, such as Finland’s, requires further adaptation and validation. Future research should focus on optimising these models for local contexts to improve clinical impact and cost-effectiveness in targeted screening programmes. Systematic review registration: PROSPERO CRD42022321391.


  • Open Access

    Association of health literacy with cancer survival: a single-centre prospective cohort study

    by Niclas Sandström, Antti Jekunen, Mikael Johansson, Heidi Andersén

    Background and purpose: Health literacy is defined as the ability to find, understand and use health information for informed decision. The role of health literacy in treatment decisions and outcome remains largely unexplored. This study sought out to assess the effect of individual health literacy on overall survival (OS) in cancer patients in Ostrobothnia. Material and methods: The present study is a follow-up of a cross-sectional survey study performed during December 2021 and March 2022. The survey assessed socioeconomic factors, lifestyle factors and self-reported health literacy. The follow-up included data on recorded death, cause of death, performance status (PS), clinical frailty scale, Charlson comorbidity index and body mass index. The sample size for this study was 400 participants, and any participant with a malignancy was eligible for the study. Results: Low health literacy was associated with increased risk of death. The disparity remained after adjustments for age, sex, comorbidities, PS, stage and hazard ratios (HR) = 1.47 (1.01–2.14). After adjustments for lifestyle patterns, the disparity remained, HR = 1.49 (1.03–2.17). The difference diminished after adjustments for cancer types. The median OS was 3.6 months longer for those with medium-high health literacy than those with low health literacy. Interpretation: The results indicated health literacy having a direct, clinically significant, effect on OS, which is likely not explained by differences in cancer entity alone. Future studies should focus on assessing whether an intervention aiming to improve health literacy may improve overall cancer survival.


  • Open Access

    Socioeconomic status and lifestyle patterns in the most common cancer types-community-based research

    by Niclas Sandström, Mikael Johansson, Antti Jekunen, Heidi Andersén

    Introduction: As the global burden of chronic cancer increases, its correlation to lifestyle, socioeconomic status (SES) and health equity becomes more important. The aim of the present study was to provide a snapshot of the socioeconomic and lifestyle patterns for different cancer types in patients at a Nordic tertiary cancer clinic. Materials and methods: In a descriptive observational study, questionnaires addressed highest-attained educational level, occupational level, economy, relationship status, exposures, and lifestyle habits. The questionnaire was distributed to all cancer patients attending the cancer clinic. Treating physicians added further information about the cancer disease, including primary origin, pathology report, TNM-classification and stage. Results: Patients with lung cancer had the lowest SES, and patients with gastrointestinal (GI) cancer, other cancer types and prostate cancer had the second, third and fourth lowest SES, respectively. However, breast cancer patients had the highest SES. Lifestyle and exposure patterns differed among the major cancer types. Lung cancer patients reported the highest proportion of unfavourable lifestyle and exposure patterns, and patients with GI cancer, prostate cancer and other cancer types had the second, third and fourth highest proportion of unfavourable lifestyle and exposure patterns, respectively. The most favourable exposure and lifestyle patterns were observed in breast cancer patients. Conclusions: The present study indicated significant socioeconomic and lifestyle differences among cancer types at a Nordic cancer centre, with differences in lifestyle being more prominent than socioeconomic differences.


  • Biweekly cabazitaxel as a safe treatment option for metastatic castration resistant prostate cancer (mCRPC) patients post-docetaxel: Final analysis of Prosty II trial.

    by Pirkko-Liisa Kellokumpu-Lehtinen, Timo Marttila, Antti Pekka Jekunen, Petteri Hervonen, Katariina Klintrup, Vesa V Kataja, Tapio Utriainen, Marjaana Luukkaa, Markku Leskinen, Kalevi Pulkkanen, et al.

    E16523 Background: In our Prosty I trial biweekly docetaxel (D) was better tolerated and yielded longer overall survival than standard triweekly D (Kellokumpu-Lehtinen et al. Lancet Oncol 2013;14:117-124). Our aim in Prosty II trial (NCT01558219) was to evaluate the safety of biweekly cabazitaxel (C) as post-docetaxel for mCRPC. Methods: Atotal of 60patients (pts) with mCRPC received C 16 mg/m² i.v. on day 1 and day 14 at 4 week cycles plus daily prednisone. The inclusion criteria; mCRPC post-D, WHO performance status (PS) < 2, age > 18 yrs and adequate bone marrow, liver and renal functions. The exclusion criteria; prior anti-cancer therapy or radioisotopes within 4-6 weeks, other malignant disease, use of inhibitors/inducers of cytochrome P450 3A4/5 or other serious illness. The primary endpoint was safety. Results: At baseline, WHO PS was 0 in 30%, 1 in 67% and 2 in 3% of the pts. The median serum PSA was 305 µg/L (range 3.7-2425) and the mean age 67 (range 50-79) yrs, 50% of pts had primarily mPC and 50% of pts had received prior abiraterone (n = 28) or enzalutamide (n = 2) in addition to D. A total of 253 cycles of C (twice biweekly dosing) were administered. No prophylactic G-CSF was used. The most common Grade 3/4 adverse events (CTCAE) were neutropenia 16.6%, pain 13.3%, fatigue 10.0%, anemia 5.0%, infection without neutropenia 10.0%, leucopenia 3.3%, neutropenic infection 1,7%, mucositis 1.7%, elevated ALP and limb edema both 1.7% of the pts. In addition one pulmonary embolism, one intracerebral hemorrhage and one bone fracture occurred (all Grade 4 AEs). Altogether in up to11 cycles Grade 1 AEs were reported in 3 (5.0%), Grade 2 AEs in 28 (46.7%), Grade 3 AEs in 23 (38.3%) and Grade 4 AEs in 6 pts (10.0%). Most of the patients (61%) discontinued the treatment due to progression. A confirmed PSA response ≥ 50% was recorded in 6 (10.2%) and best overall response as PR in 2 (3.4%) and as SD in 17 pts (28.8), clinical benefit ratio being 32.2%. The median survival was 12.8 months, and 19 pts (31.7%) were still alive at the end of the study. Conclusions: Our results show that biweekly cabazitaxel is a manageable treatment option for these heavily pretreated patients with advanced mCRPC. Clinical trial information: NCT01558219.


  • Defining a Good Death: A deliberative democratic view

    by Harri Raisio, Pirkko Vartiainen, Antti Jekunen

    Many attempts to define a good death have been recorded in the academic literature. In most of these attempts, the methods used have been surveys, interviews, and focus groups. These methods have yielded important information, but they have failed to provide an opportunity for public deliberation, whereby people engage collectively with an issue, consider it from all sides, and struggle to understand it. We believe that a well-orchestrated public deliberation could contribute to defining a good death. We gathered data from four deliberative forums implemented in Finland in November 2013. The results paint a picture that differs from those painted by the previous research, which focused mainly on individual and idealized views of a good death. Our findings have brought to light the messy reality of a good death. Deliberation elicited the concern that society could not provide a good death for all and in the process highlighted the lack of proper palliative care and the dominant role of healthcare professionals in defining a good death. Participants also came to terms with the inherent complexity of dying well and gained a better understanding of the challenges related to providing a good death via euthanasia. Their perspectives broadened, proving that defining a good death is a dynamic process rather than a static one.


  • Sudden tumour regression with enhanced natural killer cell accumulation in a patient with stage IV breast cancer

    by A.G. Maiche, A. Jekunen, P. Rissanen, P. Virkkunen, J. Halavaara, J.P. Turunen